The diagnosis of childhood-onset growth hormone (GH) deficiency (GHD) is not straightforward, requiring a comprehensive clinical, anthropometric, biochemical, endocrine, and neuroradiological assessment. Although pharmacological GH stimulation tests are still considered the gold standard for GHD diagnosis, they are burdened by both poor specificity and side effects. The measurement of insulin-like growth factor I (IGF-I), due to its close GH dependency, was proposed for diagnosing GHD. However, a number of factors may affect the measurements. Herein, we propose an algorithm based on both IGF-I determination and anthropometry, aimed at simplifying the diagnosis of GHD in prepubertal children.

Keywords:
Growth hormone deficiency, Insulin-like growth factor I, Short stature
1.
Rosenfeld RG, Albertsson-Wikland K, Cassorla F: Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995;80:1532–1540.
2.
Shalet SM, Toogood A, Rahim A, Brennan BM: The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998;19:203–223.
3.
Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z: Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part I: diagnosis of growth hormone deficiency. Growth Horm IGF Res 2001;11:137–165.
4.
Badaru A, Wilson DM: Alternatives to growth hormone stimulation testing in children. Trends Endocrinol Metab 2004;15:252–258.
5.
Growth Hormone Research Society: Consensus guidelines for the diagnosis and treatment of GH deficiency in childhood and adolescence: summary statement of the Growth Hormone Research Society. J Clin Endocrinol Metab 2000;85:3990–3993.
6.
Clayton PE, Price DA, Shalet SM: Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 1987;62:222–226.
7.
Cacciari E, Tassoni P, Parisi G, Pirazzoli P, Zucchini S, Mandini M, Cicognani A, Balsamo A: Pitfalls in diagnosing impaired GH secretion: retesting after replacement therapy of 63 patients defined as GH-deficient. J Clin Endocrinol Metab 1992;74:1284–1289.
8.
Nicolson A, Toogood AA, Rahim A, Shalet SM: The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol 1996;44:311–316.
9.
Moore DC, Ruvalcaba RHA, Smith EK, Kelly VC: Plasma somatomedin-C as a screening test for growth hormone deficiency in children and adolescents. Horm Res 1982;16:49–55.
10.
Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109:428–433.
11.
Mitchell H, Dattani MT, Nanduri V, Hindmarsh PC, Preece MA, Brook CGD: Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency. Arch Dis Child 1999;80:443–447.
12.
Cianfarani S, Tondinelli T, Spadoni GL, Scirè G, Boemi S, Boscherini B: Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clin Endocrinol 2002;57:161–167.
13.
Federico G, Street ME, Maghnie M, Caruso-Nicoletti M, Loche S, Bertelloni S, Cianfarani S: Assessment of serum IGF-I concentrations in the diagnosis of isolated childhood-onset GH deficiency: a proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED). J Clin Invest 2006;29:732–737.
14.
Cianfarani S, Liguori A, Boemi S, Maghnie Mohamad, Iughetti L, Wasniewska M, Street ME, Zucchini S, Aimaretti G, Germani D: Inaccuracy of IGFBP-3 assessment in the diagnosis of growth hormone deficiency from childhood to young adulthood: association to low GH-dependency of IGF-II and presence of circulating IGFBP-3 18 kDa fragment. J Clin Endocrinol Metab 2005;90:6028–6034.
15.
Baxter RC: Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91–96.
16.
Cianfarani S, Liguori A, Germani D: IGF-I and IGFBP-3 assessment in the management of childhood onset growth hormone deficiency. Endocr Dev 2005;9:66–75.
17.
Clemmons DR: Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin N Am 2007;36:109–129.
18.
Spiliotis BE, August GP, Hung W, Sonis W, Mendelson W, Bercu BB: Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA 1984;251:2223–2230.
19.
Woods K: Genetic defects of the growth-hormone-IGF axis associated with growth hormone insensitivity. Endocr Dev 2007;11:5–15.
20.
Camacho-Hubner C, Woods KA, Clark AJL, Savage MO: Insulin-like growth factor-I gene deletion. Rev Endocr Metab Disord 2002;3:357–361.
21.
Domene HM, Hwa V, Argente J, Wit JM, Camacho-Hubner C, Jasper HG, Pozo J, Van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG; on behalf of the International ALS Collaborative Group: Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009;72:129–141.
22.
Maghnie M, Ghirardello S, Genovese E: Magnetic resonance imaging of the hypothalamus-pituitary unit in children suspected of hypopituitarism: who, how and when to investigate. J Endocrinol Invest 2004;27:496–509.
23.
Mehta A, Dattani MT: Developmental disorders of the hypothalamus and pituitary gland associated with congenital hypopituitarism. Best Pract Res Endocrinol Metab 2006;22:191–206.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.